Evotec Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Evotec kazanç ve gelirin sırasıyla yıllık 74.3% ve 12.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 76.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 4.3% olacağı tahmin edilmektedir.

Anahtar bilgiler

74.3%

Kazanç büyüme oranı

76.1%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.2%
Gelir büyüme oranı	12.1%
Gelecekteki özkaynak getirisi	4.3%
Analist kapsamı	Good
Son güncelleme	15 Nov 2024

Gelecekteki son büyüme güncellemeleri

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 10

Recent updates

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Aug 03

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Apr 10

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Mar 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Jan 09

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Oct 05

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Jun 28

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

May 14

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Feb 25

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Jul 29

Kazanç ve Gelir Büyüme Tahminleri

XTRA:EVT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,026	10	58	139	9
12/31/2025	905	-38	-1	72	9
12/31/2024	806	-145	-254	-53	9
9/30/2024	777	-171	-209	-36	N/A
6/30/2024	788	-171	-246	-55	N/A
3/31/2024	777	-91	-224	-12	N/A
12/31/2023	781	-84	-180	36	N/A
9/30/2023	821	-95	-188	-14	N/A
6/30/2023	798	-103	-246	-42	N/A
3/31/2023	800	-116	-39	143	N/A
12/31/2022	751	-176	24	206	N/A
9/30/2022	698	-180	121	297	N/A
6/30/2022	684	2	194	322	N/A
3/31/2022	650	90	58	183	N/A
12/31/2021	618	216	3	122	N/A
9/30/2021	571	247	-58	86	N/A
6/30/2021	541	112	-50	93	N/A
3/31/2021	515	42	-99	20	N/A
12/31/2020	501	6	-54	45	N/A
9/30/2020	485	14	-4	62	N/A
6/30/2020	470	35	0	46	N/A
3/31/2020	462	42	43	82	N/A
12/31/2019	446	38	10	42	N/A
9/30/2019	419	61	1	29	N/A
6/30/2019	404	77	46	74	N/A
3/31/2019	398	94	109	139	N/A
12/31/2018	375	84	128	156	N/A
9/30/2018	370	63	109	135	N/A
6/30/2018	338	31	N/A	80	N/A
3/31/2018	294	20	N/A	19	N/A
12/31/2017	264	23	N/A	11	N/A
9/30/2017	215	28	N/A	64	N/A
6/30/2017	193	35	N/A	73	N/A
3/31/2017	178	36	N/A	74	N/A
12/31/2016	165	28	N/A	67	N/A
9/30/2016	160	18	N/A	5	N/A
6/30/2016	148	6	N/A	-6	N/A
3/31/2016	144	17	N/A	-2	N/A
12/31/2015	128	17	N/A	16	N/A
9/30/2015	119	12	N/A	19	N/A
6/30/2015	104	11	N/A	23	N/A
3/31/2015	93	-4	N/A	9	N/A
12/31/2014	89	-7	N/A	-4	N/A
9/30/2014	85	-29	N/A	6	N/A
6/30/2014	89	-25	N/A	2	N/A
3/31/2014	86	-27	N/A	1	N/A
12/31/2013	86	-25	N/A	7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EVT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: EVT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: EVT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: EVT şirketinin gelirinin (yıllık 12.1% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EVT şirketinin gelirinin (yıllık 12.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EVT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 4.3 %).

Evotec Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 54%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Consensus EPS estimates fall by 54%

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued